Page last updated: 2024-12-09

rhododendrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rhododendrol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID919205
CHEMBL ID1086681
SCHEMBL ID13698052
MeSH IDM0298328

Synonyms (32)

Synonym
rhododendrol
4-[(3r)-3-hydroxybutyl]phenol
CHEMBL1086681
(-)-rhododendrol
unii-97ptr2f3z8
rhododendrol, (-)-
betuligenol, (-)-
2-butanol, 4-(p-hydroxyphenyl)-
501-96-2
97ptr2f3z8 ,
(-)-betuligenol
(r)-frambinol
benzenepropanol, 4-hydroxy-alpha-methyl-, (alphar)-
(r)-(-)-rhododendrol
benzenepropanol, 4-hydroxy-alpha-methyl-, (r)-
benzenepropanol, 4-hydroxy-.alpha.-methyl-, (r)-
benzenepropanol, 4-hydroxy-.alpha.-methyl-, (.alpha.r)-
4r-(4-hydroxyphenyl)-2-butanol
SCHEMBL13698052
SFUCGABQOMYVJW-MRVPVSSYSA-N
benzenepropanol, 4-hydroxy-.alpha.-methyl-, (-)-
p-(3-hydroxybutyl)phenol, (r)-
DTXSID20198211
AKOS032948275
mfcd20274761
(r)-4-(3-hydroxybutyl)phenol
AS-18098
(r)-(-)-rhododendrol; (r)-frambinol; betuligenol; betuligenol, (-)-; rhododendrol; rhododendrol, (-)-
Q27272029
EN300-1870666
HY-N0948
CS-0016082

Research Excerpts

Overview

Rhododendrol (RD) is a potent tyrosinase inhibitor that is metabolized to RD-quinone. It may underlie the cytotoxicity of RD and leukoderma of the skin that may result.

ExcerptReferenceRelevance
"Rhododendrol (RD) is a potent tyrosinase inhibitor that is metabolized to RD-quinone by tyrosinase, which may underlie the cytotoxicity of RD and leukoderma of the skin that may result. "( NAD(P)H dehydrogenase, quinone 1 (NQO1), protects melanin-producing cells from cytotoxicity of rhododendrol.
Akasaka, T; Maesawa, C; Masuda, T; Okubo, A; Shibazaki, M; Takahashi, K; Yasuhira, S, 2016
)
2.1
"Rhododendrol is a phenolic compound that shows a tyrosinase-dependent toxicity for melanocytes and occasionally induces a vitiligo-like skin depigmentation. "( Glutathione maintenance is crucial for survival of melanocytes after exposure to rhododendrol.
Hachiya, A; Inoue, S; Kawabata, K; Kondo, M; Sato, K; Takahashi, Y; Yamaguchi, S, 2016
)
2.1

Toxicity

ExcerptReferenceRelevance
" Our results help to elucidate the development mechanisms of RD-induced leukoderma and provide information for innovation of safe skin-whitening compounds."( 4-(4-Hydroxyphenyl)-2-butanol (rhododendrol)-induced melanocyte cytotoxicity is enhanced by UVB exposure through generation of oxidative stress.
Goto, N; Ito, S; Masaki, T; Nagai, H; Nishigori, C; Tsujimoto, M; Wakamatsu, K, 2018
)
0.77
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID480668Inhibition of anti-DNP-IgE-induced degranulation in rat RBL2H3 cells assessed as betahexosaminidase released at 100 uM after 20 mins by microplate reader assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Inhibition of antigen-induced degranulation by aryl compounds isolated from the bark of Betula platyphylla in RBL-2H3 cells.
AID480667Inhibition of anti-DNP-IgE-induced degranulation in rat RBL2H3 cells assessed as betahexosaminidase released at 10 uM after 20 mins by microplate reader assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Inhibition of antigen-induced degranulation by aryl compounds isolated from the bark of Betula platyphylla in RBL-2H3 cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (57)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.75)18.2507
2000's0 (0.00)29.6817
2010's42 (73.68)24.3611
2020's14 (24.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.15 (24.57)
Research Supply Index4.11 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (5.26%)5.53%
Reviews5 (8.77%)6.00%
Case Studies2 (3.51%)4.05%
Observational0 (0.00%)0.25%
Other47 (82.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]